Characterizing the heterogeneous metabolic progression in idiopathic REM sleep behavior disorder

• Main Authors: Xianhua Han, Ping Wu, Ian Alberts, Hucheng Zhou, Huan Yu, Panagiotis Bargiotas, Igor Yakushev, Jian Wang, Guenter Höglinger, Stefan Förster, Claudio Bassetti, Wolfgang Oertel, Markus Schwaiger, Sung-Cheng Huang, Paul Cumming, Axel Rominger, Jiehui Jiang, Chuantao Zuo, Kuangyu Shi
• Format: Article
• Language: English
• Published: Elsevier 2020-01-01
• Series: NeuroImage: Clinical
• Subjects: REM sleep behavior disorder; Parkinson’s disease; PET; FDG; Conversion
• Online Access: http://www.sciencedirect.com/science/article/pii/S2213158220301315

Objective: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of synucleinopathies such as Parkinson’s disease (PD). Positron emission tomography (PET) with 18F-FDG reveals metabolic perturbations, which are scored by spatial covariance analysis. However, the resultant pattern scores do not capture the spatially heterogeneous trajectories of metabolic changes between individual brain regions. Assuming metabolic progression occurs as a continuum from the healthy control (HC) condition to iRBD and then PD, we investigated spatial dynamics of progressively perturbed glucose metabolism in a cross-sectional study. Methods: 19 iRBD patients, 38 PD patients and 19 HC subjects underwent 18F-FDG PET. The images were spatially normalized, scaled to the global mean uptake, and automatically parcellated. We contrasted regional metabolism by group, and allocated the inferred progression to one of several possible trajectories. We further investigated the correlations between 18F-FDG uptake and the disease duration in the iRBD and PD groups, respectively. We also explored relationships between 18F-FDG uptake and the Unified Parkinson’s Disease Rating Scale motor (UPDRS III) scores in the PD group. Results: PD patients exhibited more extensive relative hyper- and hypo-metabolism than iRBD patients. We identified three dynamic metabolic trajectories, cross-sectional hypo- or hypermetabolism, cross-sectionally unchanged hypo- or hypermetabolism, cross-sectionally late hypo- or hypermetabolism, appearing only in the contrast of PD with iRBD. No correlation was found between relative 18F-FDG metabolism and disease duration in the iRBD group. Regional hyper- and hypo-metabolism in the PD patients correlated with disease duration or clinical UPDRS III scores. Conclusion: Cerebral metabolism changes heterogeneously in a continuum extending from HC to iRBD and PD groups in this preliminary study. The distinctive metabolic trajectories point towards a potential neuroimaging biomarker for conversion of iRBD to frank PD, which should be amenable to advanced pattern recognition analysis in future longitudinal studies.